Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2025.1637309OncologyCorrectionCorrection: Monocyte count combined with GTVnx is an independent prognostic factor in non-metastatic nasopharyngeal carcinoma receiving radiotherapyYangLi-Na†SongYun-Rui†ZhangHuan†TuHong-LeiLuMing-YueLiuDe-QingSuiJiang-DongLiDan*XieYue*WangYing*Radiation Oncology Center, Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, China
Edited and reviewed by: Jan Baptist Vermorken, University of Antwerp, Belgium
*Correspondence: Dan Li, lidanludan@163.com; Yue Xie, 344899525@qq.com; Ying Wang, yingwangcq@hotmail.com
†These authors have contributed equally to this work
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Correction on Monocyte count combined with GTVnx is an independent prognostic factor in non-metastatic nasopharyngeal carcinoma receiving radiotherapy By Yang L-N, Song Y-R, Zhang H, Tu H-L, Lu M-Y, Liu D-Q, Sui J-D, Li D, Xie Y and Wang Y (2025) Front. Oncol. 15:1541212. doi: 10.3389/fonc.2025.1541212peripheral blood monocyte countGTVnxnasopharyngeal carcinomaradiotherapyoverall survivalsection-in-acceptanceHead and Neck Cancer
In the published article, there was an error in the legend for Figure 3 as published. Risk classification should be low, medium and high risk rather than no risk, low risk and high risk. The corrected legend appears below.
Kaplan-Meier curves of overall survival (A) and progression-free survival (B) of patients in different risk groups.
Two Kaplan-Meier survival plots compare low, medium, and high-risk groups. Chart A shows overall survival; the low-risk group has the highest survival rate, followed by medium and high-risk (P=0.0008). Chart B shows progression-free survival with similar trends (P=0.0007). Time is measured in months.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.